Table 1.

Top Association Results for ABF and Schizophrenia at 5q32–35.3

				Function Prediction		ABF		Schizophrenia
dbSNP 137	Position (bp)	Gene	MAF	SIFT	PolyPhen2	Beta (SE)	P Value	Beta (SE)	P Value
rs6579797a	149998128	SYNPO	0.032	Tolerated	Benign	−2.01 (0.48)	3.7×10−5c	1.84 (0.63)	.0017c
rs17660042	150666946	SLC36A3	0.073	Deleterious	Probably damaging	−1.02 (0.32)	.0018	0.94 (1.00)	.010
rs2303063	147480027	SPINK5	0.47	Tolerated	Benign	0.41 (0.18)	.023	−0.52 (1.03)	.033
rs2303067	147480955	SPINK5	0.47	Tolerated	Benign	0.41 (0.18)	.023	−0.52 (1.03)	.033
rs2961944	159835658	SLU7	0.20	Tolerated	Benign	−0.40 (0.18)	.027	0.49 (0.24)	.037
rs61740602	150646888	GM2A	0.12	Tolerated	Benign	−0.56 (0.26)	.028	0.79 (0.29)	.0068
rs17551608b	167835539	WWC1	0.19	Deleterious	Possibly damaging	0.42 (0.21)	.041	−1.09 (0.39)	.0016c

^{Note: The table lists nonsynonymous variants from 5q32–35.3 with at least nominal evidence (P < .05) for association with ABF and schizophrenia. SNP rs numbers are based on dbSNP build 137. MAFs are based on maximum likelihood estimates that account for familial relationships. Predicted effects of amino acid changes on protein function are based on the SIFT and PolyPhen2 algorithms, which were obtained with the Ensembl online tool Variant Effect Predictor (VEP). For the association results, positive beta estimates (SE in parentheses) for schizophrenia correspond to increased risk. All 7 of the SNP variants presented here show the expected directions of effect for the 2 traits (ie, decrease in ABF performance corresponds with an increase in schizophrenia risk, and vice versa). ABF, Abstraction and Mental Flexibility; MAFs, Minor Allele Frequencies;}

^aG199A; aspartic acid substituted for asparagine, D67N.

^bC798T; arginine substituted for cysteine, R250C.

^cSignificant after Bonferroni correction for multiple testing (α = .05): 407 tests for ABF; 24 tests for risk of schizophrenia.